China
Africa
Explore chapters and articles related to this topic
Clinical Applications of Prescriptions Containing Bupleurum Root
Published in Sheng-Li Pan, Bupleurum Species, 2006
Specific absorbance: Measure accurately 25 ml of the oral liquid in a 250 ml flask, add 50 ml of water, heat to distill (the speed of distillation is adjusted by distillating the fixed volume in 20 to 30 minutes). Collect the distillate in a 50-ml volumetric flask, stop distillating while the distillate is almost to 50 ml, dilute with water to volume, and mix well. Transfer accurately 3 ml in 10-ml volumetric flask, add water to volume, mix well. Transfer accurately another 3 ml in a evaporating dish, evaporate to dryness on a water bath, dissolve the residue in water, and transfer to a 10-ml volumetric flask, dilute with water to volume, mix well as a blank. Carry out the method for spectrophotometry, measure the absorbance at 277 nm; the value of absorbance is not less than 0.50.
Anti-allergic actions of a Chinese patent medicine, huoxiangzhengqi oral liquid, in RBL-2H3 cells and in mice
Published in Pharmaceutical Biology, 2021
Jianbin Sun, Sixing Huang, Yao Qin, Ping Zhang, Ziwei Li, Li Zhang, Xin Wang, Ruijun Wu, Shaorong Qin, Jiayong Huo, Kunquan Xiao, Weizao Luo
HXZQ-OL (Chinese Food and Drug Administration approval number: Z50020409; Lot Number: 19050190), containing 10 traditional Chinese medicinal medicines summarized in Table 1, were manufactured by Taiji Group Chongqingfuling Pharmaceutical Co., Ltd (Chongqing, China) according to Good Manufacturing Practices. HXZQ-OL, as well as the standards of ammonium glycyrrhizinate, honokiol, magnolol, liquiritin, narirutin, hesperidin, 5-HMF and isoliquiritin, were dissolved and diluted with methanol. The major components of HXZQ-OL were quantified using an HPLC system (SHIMADZU, Kyoto, Japan) equipped with LC-20AT liquid chromatograph, SPD-M20A diode array detector, SIL-20A autosampler, CTO-20A column oven, DGU-20A5R degasser and LC solution software. The constituents of HXZQ-OL were separated using Gemini® NX-C18 column (4.6 mm × 250 mm, 5 µm; Phenomenex, CA, USA). The mobile phase was 0.4% formic acid-acetonitrile by gradient elution (0.01 min, 98:2; 8 min, 98:2; 20 min, 92:8; 30 min, 91:9; 35 min, 91:9; 45 min, 85:15; 60 min, 85:15; 75 min, 78:22; 85 min, 78:22; 95 min, 73:27; 120 min, 58:42; 145 min, 35:65; 160 min, 10:90). The column temperature was 30 °C, the flow rate was 1.0 mL/min, and the detection wavelength was set at 250 nm (glycyrrhizin, honokiol, magnolol), 276 nm (liquiritin), 284 nm (narirutin, hesperidin, 5-HMF) and 360 nm (isoliquiritin). To determine the solid content of HXZQ-OL, 10 mL sample was placed in a 25 mL evaporating dish, followed by evaporating with water bath, and then was dried at 105 C for 3 h. The solid content of HXZQ-OL was 87.9 mg/mL.
Plasma and saliva levels of three metals in waterpipe smokers: a case control study
Published in Inhalation Toxicology, 2018
Omar F. Khabour, Karem H. Alzoubi, Nihaya A. Al-Sheyab, Mohammad A. Azab, Adnan M. Massadeh, Ahmed A. Alomary, Thomas E. Eissenberg
Plasma samples were processed as previously described (Massadeh et al., 2017; Massadeh & Al-Massaedh, 2018). Briefly, each sample was thawed at room temperature, and was treated with 3 mL HNO3 and 1 mL HClO4 in a cleaned porcelain evaporating dish. The mixture was heated at 105 °C until dry. Next, 5 mL of 1% HNO3 was added to the dry mixture and subsequently filtered through 0.45-μm filter paper. The filtrate was completed to 25 mL with deionized water resulting in a clear colorless solution. The solution was kept in a polyethylene bottle and stored at 4 °C until analysis. Lab blank underwent the same procedure without blood sample. Analysis of metals was carried out using coupled plasma optical emission spectrometry (ICP-OES, VISTA-MPX, CCD simultaneous ICPOES, VARIAN, nebulizer type: glass concentric with pressure of 200 kPa) at the Department of Chemistry at Yarmouk University, Jordan. Wavelength used were Cadmium: 214.439 nm, Lead: 220.353 nm and Zinc: 213.857 nm, with plasma argon flow rate of 12 L/min, auxiliary argon flow rate of 0.6 L/min, nebulizer argon flow rate of 0.4 L/min, integration time 100 s, read delay 20 s and peristaltic pump flow rate of 1 mL/min (Massadeh et al., 2017; Massadeh & Al-Massaedh, 2018).
Introduction of magnetic and supermagnetic nanoparticles in new approach of targeting drug delivery and cancer therapy application
Published in Drug Metabolism Reviews, 2020
Zhila Mohajeri Avval, Leila Malekpour, Farzad Raeisi, Aziz Babapoor, Seyyed Mojtaba Mousavi, Seyyed Alireza Hashemi, Marjan Salari
The synthesis process of graphene/SrFe12O19 nanocomposites is schematically illustrated in Figure 2. The REGO powder was first dispersed in deionized water by sonication using an ultrasonic homogenizer (Bandelin Sonopuls, HD 2200) for 1 h to transform the remaining carboxylic acid groups on the edges of graphene layers to carboxylate anions. In this study, SrFe12O19 nanoparticles were synthesized by the citrate solegel combustion method. Stoichiometric amounts of Fe(NO3)3.9H2O and Sr(NO3)2 (Fe/Sr ratio of 11) were dissolved in a minimum amount of deionized water by stirring at 50 °C. Citric acid was then added into the Sr2+ and Fe3+ solution to chelate these ions by adjusting the molar ratio of citric acid/metal ions as 1:1. This solution was gradually and dropwise added to the REGO suspension at room temperature and the mixture was vigorously stirred under a nitrogen flow for 30 min. Then ammonia was added to the mixture to adjust the pH value to 7. The suspension was slowly evaporated to create a viscous black gel via keeping the temperature of mixture at 80 °C and stirring constantly. The precursor gel was transferred to an evaporating dish and the heated up to temperature of 140–150 °C. At this step, the precursors gel was self-ignited and combusted rapidly to form a brown powder. The resulting self-standing fluffy powder of REGO/SrFe12O19 nanocomposite was pre-calcined at 450 °C for 4 h and then sintered at 1100 °C for an hour. The synthesis route was also repeated by using of EG and EGO powders to prepare EG/SrFe12O19 and EGO/SrFe12O19 nanocomposites to compare the structural and microwave absorbing performances of such material to the REGO/SrFe12O19.